Literature DB >> 8611499

Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.

H M Vu1, R de Lorimier, M A Moody, B F Haynes, L D Spicer.   

Abstract

A critical problem to overcome on HIV vaccine design is the variability among HIV strains. One strategy to solve this problem is the construction of multicomponent immunogens reflective of common HIV motifs. Currently, it is not known if these motifs should be based primarily on amino acid sequence or higher-order structure of the viral proteins of a combination of the two. In this paper, we report NMR-derived solution conformations for a sympathetic peptide taken from the C4 and V3 domains of HIV-1 CAN0A gp120 envelope protein. This peptide, designated T1-SP10CAN0(A), is compared to a recently reported C4-V3 peptide. T1-SP10RF(A) from the HIV-1 RF strain [de Lorimier et al. (1994) Biochemistry 33, 2055-2062], in terms of conformational features and immune responses in mice [Haynes et al. (1995) AIDS Res. Hum. Retroviruses 11, 211-221]. The T1 segment of 16 amino acids from the gp120 C4 domain is identical in both peptides and exhibits nascent helical character. The SP10 region, taken from the gp120 V3 loop, differs from that of T1-SP10RF(A) in both sequence and conformations. A reverse turn is observed at the conserved GPGX sequence. The rest of the Sp10 domain is extended with the exception of the last three residues which show evidence for a helical arrangement. Modeling of the turn region of the T1-SP10CAN0(A) peptide shows exposure of a continuous apolar stretch of side chains similar to that reported in the crystal structure of a V3 peptide from HIV-1 MN complexed with a monoclonal antibody [Rini et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 6325-6329]. this hydrophobic patch is interrupted by a charged Lys residue in the T1-SP10RF(A) peptide. This observation suggests that the HIV-1 CAN0A and HIV-1 RF C4-V3 peptides can induce widely different anti-HIV antibodies. consistent with immunogenic results.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611499     DOI: 10.1021/bi952665x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

Review 1.  HIV vaccine development at Duke University Medical Center.

Authors:  B F Haynes; H X Liao; H F Staats; M S Alam; K J Weinhold; D C Montefiori
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements.

Authors:  J J Balbach; J Yang; D P Weliky; P J Steinbach; V Tugarinov; J Anglister; R Tycko
Journal:  J Biomol NMR       Date:  2000-04       Impact factor: 2.835

3.  Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Susan Zolla-Pazner; Ian A Wilson
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Authors:  Barney S Graham; M Juliana McElrath; Michael C Keefer; Kyle Rybczyk; David Berger; Kent J Weinhold; Janet Ottinger; Guido Ferarri; David C Montefiori; Don Stablein; Carol Smith; Richard Ginsberg; John Eldridge; Ann Duerr; Pat Fast; Barton F Haynes
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

5.  Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies.

Authors:  H M Vu; D Myers; R de Lorimier; T J Matthews; M A Moody; C Heinly; J V Torres; B F Haynes; L Spicer
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.